MaxCyte
MaxCyte [MXCT] is a global, clinical-stage, cell-based therapy and life sciences company. As the inventors of the industry standard, non-viral cell-engineering technology, the company helps bring the potential of next-generation cell and gene-editing therapies to life. The company’s technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the company has now entered into ten clinical/commercial license agreements with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.maxcyte.com
Related News
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.